Evidence map›Paper›PMID 39022007›Full record

ArticleHeliyon2024

A bibliometric study of the intellectual base and global research hotspots for single-cell sequencing [2009-2022] in breast cancer.

Shan Liu, Xudong Li, Ying Zhang, Yuhan Deng, Zehao Li, Yunan Zhu, Xue Li, Yuefeng Shang, Guang Yang, Xiaolu Zhan and 2 more

Abstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shan LiuDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Xudong LiDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Ying ZhangDepartment of Neurology, Air Force Medical Center, PLA, Beijing, China.
Yuhan DengDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Zehao LiJiamusi University School of Clinical Medicine, Jiamusi, China.
Yunan ZhuDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Xue LiDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Yuefeng ShangDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Guang YangDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Xiaolu ZhanDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Yingpu LiDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
He RenDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Breast cancer is the most widespread malignant tumor worldwide. Single-cell sequencing technology offers novel insights and methods to understand the onset, progression, and treatment of tumors. Nevertheless, there is currently an absence of a thorough and unbiased report on the comprehensive research status of single-cell sequencing in breast cancer. This study seeks to summarize and quantify the dynamics and trends of research on breast cancer single-cell sequencing by bibliometric analysis. Methods: Research articles and reviews related to breast cancer single-cell sequencing were selected from the WoSCC database. Visualization of data regarding countries, institutions, authors, references, and keywords was performed by CiteSpace and VOSviewer software. Results: 583 articles and reviews were analyzed in this study. The quantity of publications related to breast cancer single-cell sequencing has been increasing annually. These studies originate from 302 institutions in 46 countries, with YMAX S WICHA producing the most publications and WANG Y being the most cited author. Conclusion: Breast cancer single-cell sequencing is a rapidly growing area of scientific interest. Future research requires more frequent and in-depth collaborations among countries, institutions, and authors. Furthermore, "clonal evolution," "tumor microenvironment," and "immunotherapy" are likely to become major focal points in upcoming research on breast cancer single-cell sequencing.

Indexed as

Bibliometric analysisBreast cancerImmunotherapyResearch hotspotsSingle-cell sequencing

Identifiers

PMID39022007
PMCPMC11252796

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.